Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells

• Serena Vella ,

  Contributed equally to this work with: Serena Vella, Elisa Tavanti

  Affiliation Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Italy

  ⨯
• Elisa Tavanti ,

  Contributed equally to this work with: Serena Vella, Elisa Tavanti

  Affiliation Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Italy

  ⨯
• Claudia Maria Hattinger,

  Affiliation Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Italy

  ⨯
• Marilù Fanelli,

  Affiliation Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Italy

  ⨯
• Rogier Versteeg,

  Affiliation Department of Human Genetics, Academic Medical Center, University of Amsterdam, The Netherlands

  ⨯
• Jan Koster,

  Affiliation Department of Oncogenomics, Academic Medical Center, University of Amsterdam, The Netherlands

  ⨯
• Piero Picci,

  Affiliation Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Italy

  ⨯
• Massimo Serra

  * E-mail: massimo.serra@ior.it

  Affiliation Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Italy

  http://orcid.org/0000-0003-0742-1177

  ⨯